ArticleClinical and molecular hepatology2023
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study.
Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- BEAT-B Study (Behavior, Aspirations, and Treatment Needs): A Mixed-Methods Study of Patient Values, Preferences, and Barriers to Care Among People Living With Chronic Hepatitis B in South and Southeast Asia.Journal of gastroenterology and hepatology · 2026Article
- Mechanism of FXR signaling: from liver inflammation to hepatocellular carcinoma.Biochemistry and biophysics reports · 2026Review
- Liver cancer in Japan: epidemiological transition, viral hepatitis control, and emerging challenges.The Lancet regional health. Western Pacific · 2026Review
- KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clinical and molecular hepatology · 2026Article
- In-Hospital Hepatitis C Alarm System: A Strategy to Enhance Linkage to Care for Hepatitis C Virus Infection.Gut and liver · 2026Article
- Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks.Clinical and molecular hepatology · 2026Article
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study.BMC infectious diseases · 2025Article
- Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study.Journal of global health · 2025Article
- Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study.Gut and liver · 2025Article
- A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles.The lancet. Gastroenterology & hepatology · 2025Review
- Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005-2022).BMC public health · 2025Article
- HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on "Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness".Clinical and molecular hepatology · 2025Article
- Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on "Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness".Clinical and molecular hepatology · 2025Article
- Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021.Hepatology international · 2025Article
- Correspondence to letter to the editor on "Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults".Clinical and molecular hepatology · 2025Article
- Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults.Clinical and molecular hepatology · 2025Article
- Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.Global health & medicine · 2024Article
- Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease.International journal of molecular sciences · 2024Review
- Elimination of viral hepatitis: How far are we?: Editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study".Clinical and molecular hepatology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND/
aimsTo eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
methodsWe analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
resultsAccording to data from 2018-2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
conclusionMany of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.